The PROGRESS trial three years later: time for more action, less distraction

BMJ. 2004 Oct 23;329(7472):970-1. doi: 10.1136/bmj.329.7472.970.

Authors

Stephen Macmahon¹, Bruce Neal, Anthony Rodgers, John Chalmers

Affiliation

¹ The George Institute for International Health, University of Sydney, PO Box M201, Sydney, NSW 2050, Australia.

No abstract available

Publication types

Comment

MeSH terms

Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Antihypertensive Agents / therapeutic use*
Data Interpretation, Statistical
Double-Blind Method
Drug Therapy, Combination
Humans
Hypertension / drug therapy*
Indapamide / therapeutic use*
Perindopril / therapeutic use*
Randomized Controlled Trials as Topic
Risk Factors
Secondary Prevention
Stroke / prevention & control*

Substances

Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Indapamide
Perindopril